• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

    7.560 -0.380 (-4.79%)
    Streaming Delayed Price Updated: 11:07 AM EDT, May 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about ARS Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment ↗
    Via Chartmill
    News headline image
    ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗
    ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening bell. Analysts expect a loss of 54 cents per share. 
    Via Benzinga
    News headline image
    ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 10, 2025 ↗
     
    Via Benzinga
    News headline image
    Earnings Outlook For ARS Pharmaceuticals ↗
     
    Via Benzinga
    News headline image
    neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗
    These two biotechs only have one marketable therapy each, but both have blockbuster potential. 
    Via The Motley Fool
    News headline image
    ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma SPRY Q3 2025 Earnings Call Transcript ↗
    ARS Pharma SPRY Q3 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    ARS Pharmaceuticals Inc (NASDAQ:SPRY) Tops Q3 2025 Revenue Forecasts Amid Wider-Than-Expected Loss ↗
    ARS Pharma beats Q3 2025 revenue estimates with strong neffy sales. The company reports a wider loss but shows robust commercial growth and global expansion. 
    Via Chartmill
    News headline image
    ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment ↗
    ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardiovascular concerns. 
    Via Benzinga
    News headline image
    neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.